These features make KLOW of interest in research on injury recovery, skin health, inflammation control, and overall tissue repair, though it is still experimental and not approved for medical use
16 Risk of nutrient deficiencies: GLP-1 agonists significantly reduce appetite, gastrointestinal motility, and nutrient absorption, leading to reduced calorie and protein intake
This means that doctors are prescribing the drug off-label, presumably for another condition, such as weight loss
Theres a lot of work left to do, but we are energized by the pace of our recent progress and remain convinced that our implants could have a profoundly positive impact for patients, their caregivers, and the healthcare system
And just like that, the door flew open